Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 69
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Geriatr Psychiatry Neurol ; 35(4): 622-626, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-34467821

RESUMEN

OBJECTIVE: Prior research suggests that restless leg syndrome (RLS) is prevalent in Parkinson's disease (PD) with insufficient evidence to support the relationship between RLS, PD, and pain. This study explored the relationship between pain in PD patients and its association with the prevalence and severity of RLS. METHOD: 127 PD patients were assessed for PD and RLS using the U.K. Brain bank Criteria and the Restless Leg Syndrome diagnostic criteria, respectively. These patients were also assessed for pain perception and interference using the Brief Pain Inventory. RESULTS: The results demonstrated Parkinson's disease patients who reported pain scored 23 more Restless Leg Syndrome prevalence points (p < 0.05), and 8.5 counts higher for Restless Leg Syndrome severity (p < 0.05) compared to the group of Parkinson's disease patients denying pain. DISCUSSION: The presence of pain in PD patients indicated a higher RLS prevalence and an increased RLS severity. This finding suggests patients suffering from pain interference may experience more severe RLS symptoms. This demonstrates an inextricable link and association between pain in PD patients and RLS. Further robust investigations are required to elucidate any potential causative links, which can inform more holistic treatment principles.


Asunto(s)
Enfermedad de Parkinson , Síndrome de las Piernas Inquietas , Estudios Transversales , Humanos , Dolor/complicaciones , Dolor/epidemiología , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/diagnóstico , Enfermedad de Parkinson/epidemiología , Prevalencia , Síndrome de las Piernas Inquietas/complicaciones , Síndrome de las Piernas Inquietas/diagnóstico , Síndrome de las Piernas Inquietas/epidemiología
2.
Acta Neurol Scand ; 144(2): 115-131, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-33982803

RESUMEN

Among the various non-motor symptoms of Parkinson's disease (PD), pain is often cited as the most common and debilitating feature. Currently, the literature contains gaps in knowledge with respect to the various forms of treatment available, particularly non-pharmacological therapies. Thus, the purpose of this systematic review is to provide an examination of the literature on non-pharmacological therapies for pain in PD. We compared the findings of research articles indexed within various literature databases related to non-pharmacological treatments of pain in PD patients. Our review identified five major non-pharmacological methods of pain therapy in PD: acupuncture, hydrotherapy, massage therapy, neuromodulation, and exercise. Treatments such as exercise therapy found a reduction in pain perception due to various factors, including the analgesic effects of neurotransmitter release during exercise and increased activity leading to a decrease in musculoskeletal rigidity and stiffness. By the same token, hydrotherapy has been shown to reduce pain perception within PD patients, with authors often citing a combined treatment of exercise and hydrotherapy as an effective treatment for pain management. Multiple methods of neurostimulation were also observed, including deep brain stimulation and spinal cord stimulation. Deep brain stimulation showed efficacy in alleviating certain pain types (dystonic and central), while not others (musculoskeletal). Hence, patients may consider deep brain stimulation as an additive procedure for their current treatment protocol. On the other hand, spinal cord stimulation showed significant improvement in reducing VAS scores for pain. Finally, although the literature on massage therapy and acupuncture effectiveness on pain management is limited, both have demonstrated a reduction in pain perception, with common reasons such as tactile stimulation and release of anti-nociceptive molecules in the body. Although literature pertaining to non-pharmacological treatments of pain in PD is sparse, there is copious support for these treatments as beneficial to pain management. Further exploration in the form of clinical trials is warranted to assess the efficacy of such therapies.


Asunto(s)
Manejo del Dolor/métodos , Dolor/etiología , Enfermedad de Parkinson/complicaciones , Analgesia por Acupuntura/métodos , Terapia por Ejercicio/métodos , Humanos , Hidroterapia/métodos , Masaje/métodos , Estimulación Eléctrica Transcutánea del Nervio/métodos
3.
Neurol Sci ; 41(10): 2691-2701, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32358706

RESUMEN

Peripheral neuropathy (PN) is a common neurological problem defined as a dysfunction of sensory, motor, and autonomic nerves. The presence of peripheral neuropathy has recently been noticed in Parkinson's disease (PD) This comorbidity is concerning as it increases the burden on patients whose motor functions are previously compromised. A comprehensive computer-based literature review utilizing multiple peer-reviewed databases (e.g., Embase, PsycINFO, CINAHL, etc.) was conducted. There is evidence for the utility of robust diagnostic criteria to distinguish between large fiber neuropathy (LFN) and small fiber neuropathy (SFN). Some studies have established links between prolonged L-DOPA exposure and prevalence with increased levels of homocysteine (HCY) and methylmalonic acid (MMA) as pathological underlying mechanisms. PN in PD patients with relatively truncated exposure to L-DOPA therapy may have underlying mutations in the Parkin and MHTFR gene or separate mitochondrial disorders. Vitamin B12 and cobalamin deficiencies have also been implicated as drivers of PN. Accumulation of phosphorylated α-synuclein is another central feature in PN and deems urgent exploration via large cohort studies. Importantly, these underlying mechanisms have been linked to peripheral denervation. This review delves into the potential treatments for PN targeting B12 deficiencies and the use of COMT inhibitors along with other novel approaches. Avenues of research with powerful randomized controlled and long-term cohort studies exploring genetic mechanisms and novel treatment pathways is urgently required to alleviate the burden of disease exerted by PN on PD.


Asunto(s)
Enfermedad de Parkinson , Enfermedades del Sistema Nervioso Periférico , Humanos , Levodopa , Ácido Metilmalónico , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/epidemiología , Enfermedades del Sistema Nervioso Periférico/diagnóstico , Enfermedades del Sistema Nervioso Periférico/epidemiología , Enfermedades del Sistema Nervioso Periférico/etiología , Vitamina B 12
4.
Int J Neurosci ; 129(8): 746-753, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-30616495

RESUMEN

Objectives: Although there have been numerous studies conducted to better understand Parkinson's disease (PD), the epidemiology of its debilitating non-motor symptoms across different ethnicities remains understudied. Herein we explore the relationship between depression, anxiety and pain in PD patients of Caucasian or Indian ethnicity (PD Caucasians and PD Indians). Patients and Methods: All patients and healthy age and gender matched controls were assessed via semi-structured interviews for anxiety, pain and depression using structured questionnaires. Results: PD Indians did not differ from PD Caucasians on anxiety or depression. However, PD Caucasians were more likely to report aching pain by 80 times and dull pain by 108 times compared to PD Indians. PD Indians were 82% less likely to have pain interfering with social activities, and 90% less likely to have pain interfering with relations with others compared to PD Caucasians. Conclusion: Although an Indo-Caucasian difference may not be detected from mood dysfunction, important differences may exist from the influence of pain interfering with several dimensions of life.


Asunto(s)
Ansiedad/etnología , Depresión/etnología , Dolor/etnología , Enfermedad de Parkinson/etnología , Población Blanca/etnología , Anciano , Anciano de 80 o más Años , Ansiedad/etiología , Depresión/etiología , Femenino , Humanos , India/etnología , Masculino , Persona de Mediana Edad , Ontario/etnología , Dolor/etiología , Enfermedad de Parkinson/complicaciones
5.
Neuroepidemiology ; 51(3-4): 190-206, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30153669

RESUMEN

Pain in Parkinson's disease (PD) is a debilitating symptom with a prevalence of 68%, yet is untreated 50% of the time. What is unclear, however, is which treatment is optimal for minimizing pain severity in PD. Thus, the objective of this systematic review and meta-analysis was to investigate the efficacy of a variety of novel, complimentary, and conventional treatments for pain in PD and elucidate which therapy is the most effective. A systematic search was performed using MEDLINE, PsycINFO, Embase, CINAHL, and CENTRAL databases. To identify additional articles, manual searches of reference lists of included trials were also searched. Major neurology conference proceedings occurring between January 2014 and February 2018 were also searched to identify unpublished studies that may be potentially eligible. Twenty-five randomized controlled trials that encompassed medical, surgical, and complementary therapies met our inclusion criteria and exhibited moderate quality evidence. Two reviewers conducted assessments for study eligibility, risk of bias, data extraction, and quality of evidence rating. A conservative random-effects model was used to pool effect estimates of pain severity. The greatest reductions in pain were found with safinamide (Standardized mean difference = -4.83, 95% CI [-5.07 to -4.59], p < 0.0001), followed by cannabinoids and opioids, multidisciplinary team care, catechol-O-methyltransferase inhibitors, and electrical and Chinese therapies. Moderate effects in reducing pain were in pardoprunox and surgery, while the weakest effects were in dopaminergic agonists and miscellaneous therapies. Safinamide is an important adjunct to standard parkinsonian medication for alleviating pain in PD.


Asunto(s)
Manejo del Dolor/métodos , Dolor/etiología , Enfermedad de Parkinson/complicaciones , Alanina/análogos & derivados , Alanina/uso terapéutico , Analgésicos/uso terapéutico , Bencilaminas/uso terapéutico , Terapia por Estimulación Eléctrica , Humanos
6.
Int J Neurosci ; 126(8): 734-8, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26289746

RESUMEN

Anxiety and depression are common in Parkinson's disease (PD) patients, yet their prevalence and severity compared to individuals without PD requires more research. Moreover, it has never been compared across different ethnic groups. The objective of this study was to close that gap in the literature by exploring the caseness and severity of anxiety and depression in PD patients of different ethnicities compared to controls without PD. It was found that caseness and severity of anxiety and depression are higher in individuals with PD compared to controls. Furthermore, the caseness and severity of anxiety and depression do not vary significantly among ethnic groups. Finally, depression caseness was not predicted by age, gender, disease duration, restless legs syndrome prevalence, Hoehn and Yahr (H&Y) score nor Unified Parkinson's disease rating scale part III (UPDRS-III) score. Anxiety caseness was predicted by gender, with females 2.7 times more likely to have anxiety caseness than males. Overall, our study suggests that treatment plans should be individualized based on prevalence and severity of the two conditions in individuals with PD rather than generalize treatment for specific ethnic groups.


Asunto(s)
Ansiedad/etnología , Depresión/etnología , Trastornos del Humor/etnología , Enfermedad de Parkinson/etnología , Anciano , Anciano de 80 o más Años , Ansiedad/etiología , Canadá/etnología , Estudios de Casos y Controles , Depresión/etiología , Femenino , Humanos , India/etnología , Masculino , Región Mediterránea/etnología , Persona de Mediana Edad , Trastornos del Humor/etiología , Enfermedad de Parkinson/complicaciones , Población Blanca/etnología
7.
Int J Neurosci ; 126(2): 116-20, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-25469455

RESUMEN

PURPOSE/AIMS: The objectives of the study were to analyze the association between Parkinson's disease and restless legs syndrome, and to explore the relationship between mood disorder comorbidity (anxiety and depression), pain, and restless legs syndrome. METHODS: This study included 123 Parkinson's disease patients and 123 non-Parkinson's disease patients matched for age and gender, and evaluated for anxiety severity, depression severity, pain severity, pain interference, pain disability, and restless legs syndrome prevalence. This was performed using semi-structured interviews and a neurological examination through the restless legs syndrome diagnostic criteria and the following inventories; Hospital Anxiety and Depression Scale, Brief Pain Inventory, and Pain Disability Index. RESULTS: Parkinson's disease patients had significantly greater anxiety severity, depression severity, pain severity, pain interference, pain disability, and restless legs syndrome prevalence in comparison to controls. In addition, Parkinson's disease patients' comorbid for anxiety and depression had significantly greater pain severity, pain interference, and pain disability, but not RLS prevalence, in comparison to Parkinson's disease only, Parkinson's disease anxiety, and Parkinson's disease depression patients. CONCLUSIONS: Pain interference, pain severity, and pain disability is greater among Parkinson's disease patients with anxiety and depression, in comparison to Parkinson's disease patients without anxiety and depression. On the contrary, the prevalence of restless legs syndrome was not found to be relevant.


Asunto(s)
Trastornos del Humor/etiología , Dolor/etiología , Enfermedad de Parkinson/complicaciones , Síndrome de las Piernas Inquietas/etiología , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Evaluación de la Discapacidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Examen Neurológico , Dimensión del Dolor , Escalas de Valoración Psiquiátrica , Estadísticas no Paramétricas
9.
Int J Neurosci ; 125(4): 253-5, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24894049

RESUMEN

Essential tremor (ET) and Parkinson's disease (PD) tremor differ in type, frequency and distribution. Despite being two separate disorders, there have been cases reported of comorbidity for ET-PD. Studies have reported an increase in the incidence of ET in relatives of patients with PD, yet the risk of developing PD in ET patients has not been thoroughly investigated. Our study set out to determine the incidence of precedent ET in PD patients. We conducted a retrospective chart review analysis of 332 idiopathic PD patients to determine how many of them had ET prior to the diagnosis of PD and the percentage of them who were also diagnosed with ET. Our results indicate that the prevalence of precedent ET among a population of idiopathic PD patients was not any higher than the prevalence of ET in a comparable general population. Our results support the notion that ET and PD are mutually independent disorders. Further studies are needed to understand the exact relationship between these two disorders.


Asunto(s)
Temblor Esencial/epidemiología , Enfermedad de Parkinson/epidemiología , Adulto , Femenino , Humanos , Masculino , Prevalencia , Estudios Retrospectivos
10.
Eur Neurol ; 70(1-2): 42-5, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23711510

RESUMEN

BACKGROUND: Parkinson's disease (PD) is commonly characterized by its motor symptoms such as resting tremor, rigidity, bradykinesia and postural instability; however, some of the most debilitating symptoms of this disease are non-motor ones such as dementia and sialorrhea (drooling). Drooling is caused by impaired swallowing and it can have a significant impact on the quality of life. However, it is still unclear whether cognitive dysfunction could exacerbate drooling. We wanted to examine if any relationship existed between drooling and dementia in PD patients. Identifying the correlation will aid physicians to screen and initiate early management of drooling in the course of PD. This can possibly lead to improvements in the quality of life in these patients. METHODS: In this retrospective study, we investigated the prevalence of drooling in 314 PD patients and further compared the difference in the prevalence of drooling in patients with dementia and without dementia. In addition, we studied the impact of gender on drooling in this patient population. RESULTS: Our results show that a significant correlation exists between drooling and dementia in our sample of PD patients. Furthermore, in males, the correlation between the prevalence of drooling and dementia was found to be clinically significant as compared to the female population. CONCLUSION: Our findings suggest that drooling is a major concern in the course of PD and should therefore be addressed early and more aggressively in patients with dementia.


Asunto(s)
Demencia/etiología , Enfermedad de Parkinson/complicaciones , Sialorrea/etiología , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Factores Sexuales , Sialorrea/epidemiología
11.
Psychiatry Clin Neurosci ; 67(7): 509-16, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23992392

RESUMEN

AIM: While much research has been conducted towards understanding the basis of visual hallucinations in Parkinson's disease, little has focused on characterizing the content and patients' emotional experience. These factors are likely very influential on a patient's decision to seek treatment, a critical aspect of any symptom from the clinical perspective. METHODS: A retrospective chart analysis was performed on Parkinson's disease patients seen in a community-based Parkinson's Disease and Movement Disorder Clinic between 2005 and 2010. RESULTS: The study consisted of 334 patients with Parkinson's disease, among whom 10.5% had visual hallucinations. Hoehn and Yahr disease stage (P = 0.001), concurrent presence of dementia (P = 0.001),and sex (P = 0.031) were significant onset predictors. The most significant determinant of treatment-seeking was emotional reaction, namely whether hallucinations were bothersome (P = 0.008). However, the specific type of content during hallucinations was sometimes more influential and contradicted emotional response. CONCLUSION: Although treatment-seeking can be predicted by how individuals feel about hallucinations, a patient's decision may not be logically consistent. We suggest that clinicians offer treatment based on patients' recollections and opinions.


Asunto(s)
Alucinaciones/terapia , Enfermedad de Parkinson/complicaciones , Anciano , Anciano de 80 o más Años , Femenino , Alucinaciones/complicaciones , Alucinaciones/psicología , Humanos , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/psicología , Aceptación de la Atención de Salud , Estudios Retrospectivos
12.
Int J Neurosci ; 123(7): 503-6, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23336737

RESUMEN

OBJECTIVE: The aim of this study is to identify the prevalence of impulse compulsive disorder (ICD) in Parkinson's disease (PD) patients and to study potential associative factors that may be related to the onset of ICD while on parkinsonian medications. METHOD: The study was conducted in two parts. In Part A, the prevalence of ICD in 140 PD patients was first assessed, followed by identifying any common variables that may be associated with the development of ICD. Finally, using a detailed chart review, Part B of the study examined the prevalence of ICD in all patients who presented with identical risk factors gathered in Part A. RESULTS: Of the 140 patients, 8 patients developed symptoms of ICD. Seven of these patients were found to have five common variables that included gender (males), stages 1-2 of PD, young onset of PD, maximum dosage of the drug and the use of dopamine agonists (DAs). Of the 140 patients, 22 patients fit the above-mentioned five criteria and of those 22 patients, 33% developed symptoms of ICD. CONCLUSION: The use of DA therapy in the treatment of PD patients should be carefully monitored, especially in younger male patients who exhibit early signs of parkinsonian symptoms. As such, it is crucial for physicians to adjust DA dosages while also seeking alternative treatments to avoid the risk of ICD while on DAs.


Asunto(s)
Trastornos Disruptivos, del Control de Impulso y de la Conducta/inducido químicamente , Trastornos Disruptivos, del Control de Impulso y de la Conducta/complicaciones , Agonistas de Dopamina/efectos adversos , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/psicología , Caracteres Sexuales , Adulto , Edad de Inicio , Anciano , Canadá/epidemiología , Trastornos Disruptivos, del Control de Impulso y de la Conducta/epidemiología , Agonistas de Dopamina/administración & dosificación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/epidemiología , Prevalencia , Factores de Riesgo
13.
Eur Neurol ; 68(5): 318-21, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23075668

RESUMEN

The objective of this study was to determine the prevalence of blepharospasm (BSP), with and without apraxia of eyelid opening (AEO), in patients with parkinsonism, cervical dystonia (CD), and essential tremor (ET). BSP, with or without AEO, is associated with parkinsonism. There have been several reports of BSP in other dystonic conditions, but few looked at the incidence of BSP in ET patients. This study included 659 patients of which 357 had parkinsonism (276 idiopathic Parkinson's disease (IPD) and 81 atypical parkinsonism (57 progressive supranuclear palsy; 11 multiple system atrophy 13 corticobasal degeneration)), 274 had ET, 22 had CD, and 6 had spinocerebellar ataxia. Our results indicate that BSP (with or without AEO) was more prevalent in atypical parkinsonism (6 out of 81, 7.41%) than IPD (9 out of 276, 3.26%). The study also followed 10 (of the 28) patients with BSP to screen for the development of other movement disorders - of these, 2 developed Parkinson's disease. We conclude then that BSP is common in parkinsonism and that BSP is more prevalent in atypical parkinsonism. We also conclude that BSP is not a common feature in ET patients (0 out of 274 patients reported BSP symptoms).


Asunto(s)
Apraxias/epidemiología , Blefaroespasmo/epidemiología , Temblor Esencial/complicaciones , Párpados/fisiopatología , Enfermedad de Parkinson/epidemiología , Tortícolis/complicaciones , Apraxias/etiología , Blefaroespasmo/complicaciones , Blefaroespasmo/diagnóstico , Blefaroespasmo/etiología , Femenino , Humanos , Masculino , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/diagnóstico , Prevalencia , Parálisis Supranuclear Progresiva/complicaciones
14.
Eur Neurol ; 67(5): 312-4, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22517489

RESUMEN

BACKGROUND/AIMS: Drooling or sialorrhea is a common non-motor symptom of Parkinson's disease (PD), and is reported by 35-75% of patients. Drooling is primarily due to impaired swallowing rather than hypersecretion of saliva. In this study, we examined the prevalence of drooling in PD and its relation to various factors such as age, stage of disease, gender and ethnicity. METHODS: A retrospective cohort chart analysis of 307 patients with idiopathic PD was conducted. These patients were seen in the Parkinson's Disease and Movement Disorders Clinic between 2005 and 2010. RESULTS: 123 (40%) patients exhibited drooling. No correlation between age and development of drooling was observed. However, gender was found to be a significant factor in developing sialorrhea. Males are twice as more likely to develop sialorrhea than females. In addition, drooling becomes more prevalent with disease progression; Hoehn and Yahr stage 4 patients being the most at risk. Ethnicity and immigration status have no relationship in developing drooling. CONCLUSIONS: Sialorrhea is seen in a significant number of PD patients. This study, to the best of our knowledge, is the most extensive clinical assessment of drooling in PD to date.


Asunto(s)
Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/etnología , Sialorrea/etnología , Sialorrea/etiología , Anciano , Anciano de 80 o más Años , Distribución de Chi-Cuadrado , Estudios de Cohortes , Progresión de la Enfermedad , Etnicidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Factores Sexuales
15.
Psychiatry Clin Neurosci ; 66(1): 64-8, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22250611

RESUMEN

AIMS: Parkinson's disease is a chronic neurodegenerative disorder characterized by bradykinesia, rigidity, and resting tremor. Dementia, among its non-motor symptoms, is a debilitating complication affecting intellectual functioning. The aim of the present study was to determine the prevalence of dementia in Parkinson's disease and its relation to age, gender and stage of the disease. METHODS: A retrospective chart analysis was performed on Parkinson's disease patients seen in a community-based Parkinson's disease and movement disorder clinic between 2005 and 2010. RESULTS: A total of 310 patients were included in this survey, among whom 61 patients (19.7%) with Parkinson's disease met the criteria for dementia. Age was found to be a significant factor in developing dementia, with 90% of patients with dementia aged ≥70. Gender, however, was not correlated with dementia in Parkinson's disease. On analysis of stage at which dementia developed, progression of the disease was positively correlated with prevalence of dementia. CONCLUSIONS: As age increases, the chances of developing dementia increase. Dementia, contrarily, is not selective between genders. The likelihood of developing dementia increases as the stage of disease advances. Further research is required in order to understand underlying mechanisms of dementia in Parkinson's disease.


Asunto(s)
Demencia/epidemiología , Enfermedad de Parkinson/psicología , Factores de Edad , Anciano , Canadá/epidemiología , Demencia/complicaciones , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/diagnóstico , Prevalencia , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Factores Sexuales
16.
Int J Neurosci ; 122(3): 119-23, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22023293

RESUMEN

Hereditary Neuropathy with Liability to Pressure Palsy (HNPP) is an autosomal dominant disorder and is usually characterized by episodes of recurrent and painless focal motor and sensory peripheral mononeuropathy. This condition is usually localized around areas of entrapment (predominantly the wrists, knees, elbows, and shoulders). The genetic locus of the disease is chromosome 17p12. A deletion of the PMP22 gene results in the lack of peripheral myelin protein, a key component to the myelin sheet of peripheral nerves. However, this disease may be completely asymptomatic until an event, such as a minor trauma, triggers these episodes, as seen in our presented case report. The diagnosis of HNPP can be somewhat challenging, as other diseases, such as Charcot-Marie-Tooth disease type 1A (CMT) and Hereditary Neuralgic Amyotrophy (HNA) must be included in the differential diagnosis due to their overlapping clinical features. There are currently no treatments to cure the disease, but therapies seek to alleviate the symptoms and recurring episodes.


Asunto(s)
Artrogriposis/genética , Artrogriposis/fisiopatología , Predisposición Genética a la Enfermedad/genética , Neuropatía Hereditaria Motora y Sensorial/genética , Neuropatía Hereditaria Motora y Sensorial/fisiopatología , Proteínas de la Mielina/deficiencia , Proteínas de la Mielina/genética , Adulto , Artrogriposis/diagnóstico , Cromosomas Humanos Par 17/genética , Diagnóstico Diferencial , Femenino , Neuropatía Hereditaria Motora y Sensorial/diagnóstico , Humanos , Nervios Periféricos/metabolismo , Nervios Periféricos/patología , Nervios Periféricos/fisiopatología
17.
Int J Neurosci ; 122(3): 114-8, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22050192

RESUMEN

A task-specific tremor (TST) is a rare form of movement disorder that appears while performing or attempting to perform a particular task. Primary writing tremor (PWT) is the most common form of TST which only occurs during the act of writing and hinders it. (Bain PG, Findley LJ, Britton TC, Rothwell JC, Gresty MA, Thompson PD, Marsden CD. MRC Human Movement, and Balance Unit, Institute of Neurology, London, UK. Primary writing tremor. Brain. 1995;118(6):1461-72.) Primary writing tremor type B is present not only during the act of writing but also when the hand assumes a writing posture. (Bain PG, Findley LJ, Britton TC, Rothwell JC, Gresty MA, Thompson PD, Marsden CD. MRC Human Movement and Balance Unit, Institute of Neurology, London, UK. Primary writing tremor. Brain. 1995;118(6):1461-72.) We first of all describe a remarkable case study of a 50-year old, right-handed male who started experiencing a primary writing tremor in his right hand about a year ago. This case was found to be of particular interest because the patient had it relatively difficult when attempting to write numbers as opposed to writing letters. This review further discusses the clinical manifestations of PWT. In addition, three main hypotheses have been proposed for the causation of PWT, although the exact pathophysiology of PWT still remains unknown. It has been suggested that PWT is a separate entity, a variant of essential tremor and not a separate entity, or a type of dystonia. The various treatment options for PWT are discussed including botulinum toxin and oral pharmacotherapy.


Asunto(s)
Trastornos Distónicos/fisiopatología , Temblor Esencial/fisiopatología , Escritura Manual , Trastornos Distónicos/diagnóstico , Trastornos Distónicos/terapia , Temblor Esencial/diagnóstico , Temblor Esencial/terapia , Humanos , Masculino , Persona de Mediana Edad , Fármacos Neuromusculares/uso terapéutico , Procedimientos Neuroquirúrgicos/métodos
18.
Int J Neurosci ; 122(7): 363-6, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22356509

RESUMEN

Livedo reticularis (LR) is a "fish-net like" mottling of the skin, and is attributed to a variety of factors. Amantadine, a medication used in Parkinson's disease, has been known to cause LR localized to the lower, and to a rarer extent, the upper extremities. Patient perception of this condition has been severely under-reported and can impact the patient's decision to stop this medication. In this retrospective study, we analyze the perception of five patients presenting with LR and their decision to continue on amantadine. It was seen that patients with the reticularis rash localized in the upper extremities, in addition to the lower extremities, were affected enough to discontinue amantadine despite its useful therapeutic effects. It is imperative that patient perception regarding LR be taken into consideration when initially presented. Furthermore, the decision to change the regiment of amantadine should be individualized according to patient condition and perception of presented rash.


Asunto(s)
Amantadina/efectos adversos , Antiparkinsonianos/efectos adversos , Livedo Reticularis/inducido químicamente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/tratamiento farmacológico , Estudios Retrospectivos
20.
Acta Neurol Belg ; 110(2): 201-2, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20873453

RESUMEN

We report a rare case of familial paroxysmal kinesigenic dyskinesia. A 42-year-old woman and her 13-year-old daughter both presented with episodic curling of their hand and arm. These events were triggered by sudden movements and would last several seconds. Both patients' symptoms were unilateral and their physical and neurological examinations were normal. Treatment with carbamazepine improved their symptoms. Although an uncommon movement disorder it is important to recognize the clinical presentation of paroxysmal kinesigenic dyskinesia as most patients respond very well to medical treatment.


Asunto(s)
Corea/genética , Corea/fisiopatología , Lateralidad Funcional/fisiología , Madres , Núcleo Familiar , Adolescente , Adulto , Femenino , Humanos , Examen Neurológico/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA